hUCB
Phase 2Biologic
hUCB is one of 57 biologic programs targeting Cerebral Palsy. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
116 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Tnkase
RochePhase 3
Ozempic
Novo NordiskPhase 3
Reminyl
WWim Janssens
Phase 3
Intravenous Thrombolysis
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Butylphthalide
PPeking Union Medical College Hospital
Phase 3
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Aggrastat
MMedicure
Phase 3
Edaravone Dexborneol
SSimcere Pharmaceutical Co., Ltd
Phase 3
Y-6
BBeijing Tiantan Hospital
Phase 3
Proamatine
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hUCB. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- SStemCyte Taiwan Co., Ltd.